KRRO-110 miss drives overhaul; KRRO-121/111 show preclinical promise. Click here to read my most recent analysis of the stock ...
Zacks Investment Research on MSN
Beam Therapeutics stock soars 21% in three months: Here's why
Shares of Beam Therapeutics BEAM have risen 21% over the past three months against the industry’s 4.5% decline, primarily ...
Prime Medicine's Prime Editing is a much more credible tool for other larger TAMs like Wilson Disease and AATD. See why PRME ...
CAMBRIDGE, Mass., May 12, 2026--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recent studies attempted to improve the risk of recurrence while reducing the risk of adverse effect Alvelestat is an investigational oral neutrophil elastase inhibitor designed to protect AATD ...
Beam Therapeutics shared positive phase I/II data for BEAM-302 in AATD across multiple doses. BEAM-302 at 60 mg led to sustained increases in total AAT and ~84% reduction in mutant Z-AAT levels. Beam ...
New research results show that a new form of gene editing is efficient in correcting a mutation in patient cells with the monogenic disease Alpha-1 antitrypsin deficiency (AATD), a common inherited ...
Regeneron and Tessera will jointly develop TSRA-196 for Alpha-1 Antitrypsin Deficiency. Tessera receives $150M plus up to $125M in milestones as both firms share costs and profits. Tessera will run ...
Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results